Search

Your search keyword '"Gasbarrini G"' showing total 3,513 results
Start Over Author "Gasbarrini G"
3,513 results on '"Gasbarrini G"'

7. Empirical first-line treatment use and effectiveness trends in Europe in the period 2013- 2020: results from the European registry on H. pylori management (HP-EUREG)

Author

O. P. Nyssen , Á. Pérez-Aísa , D. Vaira , L. Jonaitis , B. Tepes , A. Keco-Huerga , M. Castro- Fernández , A. Lucendo , D. Bordin , N. Brglez Jurecic , L. Vologzhanina, M. Caldas , G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas , G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert

Subjects
Helicobacter pylori
Abstract

Background: The impact of consensus, prescription choices and efficacy trends on clinical practice over time has not been studied in depth. Methods: International multicenter prospective non-interventional registry aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult patients were registered at AEG-REDCap e-CRF up to February 2021. Modified intention-to-treat (mITT) and time trend analyses were performed. Results: So far 29, 634 first-line empirical prescriptions from 31 European countries have been included. Overall, the most common prescribed treatments in the 2013-20 were triple therapies ; however, a shift in antibiotic regimens was identified. Triple therapies decreased from over 50% of prescription in 2013/15 to less than 20% in 2018/20. Non- bismuth concomitant therapy use decreased from 21% in 2013/14 to 13% in 2019/20, while Pylera® increased from 0-1% in 2014/2015 to 19% in 2019/20. An increase in the average duration of treatments from 11 to 13 days in 2013-2020, and of the daily dose of PPI, was identified (No trend was identified (data now shown) ; however, there was an 8% overall improvement in first-line mITT overall effectiveness from 2013 to 2020 (Table 1). Conclusions: European gastroenterological practice is constantly adapting to the newest published evidence and recommendations (reducing the use of triple therapies and increasing the duration of treatment and the dose of PPIs), with a subsequent progressive improvement in overall effectiveness.

Published
2021

8. First-line empirical H. pylori eradication therapy in Europe: results from 30,000 cases of the European registry on H. pylori management (HP- EUREG)

Author

O. P. Nyssen, Á. Pérez-Aísa, D. Vaira, L. Jonaitis, B. Tepeš, A. Keco-Huerga, M. Castro Fernández, A. Lucendo, D. Bordin, N. Brglez Jurecic, L. Vologzhanina, M. Caldas, G. Fadieienko, R. Abdulkhakov, L. Bujanda, M. Leja, M. Romano, S. Georgopoulos, V. Ntouli, Ante Tonkić, H. Simsek, A. Gasbarrini, G. M Buzas, P. Phull, M. Venerito, P. Malfertheiner, J. Kupčinskas, G. Babayeva, O. Shvets, F. Lerang, R. Marcos Pinto, T. Rokkas, I. Ilkay Simsek, S. Smith, Y. Niv, D. Lamarque, F. Heluwaert, A. Goldis, W. Marlicz, V. Milivojevic, L. Boyanova, L. Kunovský, V. Lamy, C. Beglinger, P. Bytzer, L. Capelle, I. Puig, F. Mégraud, C. O’Morain, J. P. Gisbert

Subjects
Helicobacter pylori, eradication therapy
Abstract

Introduction: The best approach for Helicobacter pylori management re-mains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.Aims & Methods: International multicentre prospective non-intervention-al registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to February 2021. Variables in-cluded: demographics, previous eradication attempts, prescribed treat-ment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per-protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability.Results: In total 41, 562 patients from 31 European countries were evaluat-ed and 29, 634 (70%) first-line empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), followed by non-bismuth concomitant treat-ment (18%) and bismuth quadruple (three-in-one single capsule) (12%), achieving 84%, 90% and 94% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadru- ple or with 14-day concomitant treatment (Table). Longer treatment dura-tion, higher acid inhibition and compliance were associated with higher eradication rates. Conclusion: Management of H. pylori infection by European gastroenter-ologists is heterogeneous. Only quadruple therapies lasting at least ten days are able to achieve over 90% eradication rates.

Published
2021

9. The healthy gluten-free diet: Practical tips to prevent metabolic disorders and nutritional deficiencies in celiac patients

Author

Rinninella, Emanuele, Cintoni, M., Raoul, Pauline Celine, Triarico, S., Dionisi, Tommaso, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E. (ORCID:0000-0002-9165-2367), Raoul P., Dionisi T., Gasbarrini G. B., Gasbarrini A. (ORCID:0000-0002-7278-4823), Mele M. C. (ORCID:0000-0003-0153-5819), Rinninella, Emanuele, Cintoni, M., Raoul, Pauline Celine, Triarico, S., Dionisi, Tommaso, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Mele, Maria Cristina, Rinninella E. (ORCID:0000-0002-9165-2367), Raoul P., Dionisi T., Gasbarrini G. B., Gasbarrini A. (ORCID:0000-0002-7278-4823), and Mele M. C. (ORCID:0000-0003-0153-5819)

Abstract

The gluten-free diet (GFD) is the cornerstone treatment for coeliac disease (CD). However, a healthy GFD is more complex than the only exclusion of gluten-containing foods. Most celiac patients do not receive nutritional advice and tend to consume industrial gluten-free products (GFPs), which often lack fiber, vitamins, and other micronutrients while being rich in saturated fats and refined sugars. This review focuses on the main potential metabolic disorders and nutritional deficiencies in CD patients at diagnosis and dissects the main nutritional and metabolic issues due to a non-balanced GFD. Nutritional tips to achieve an adequate dietary approach in CD are provided. We also compared the main nutritional components of naturally gluten-free cereals (including pseudocereals) to give an exhaustive overview of the possible healthy alternatives to processed GFPs. Clinicians and dietitians should be systematically involved in the diagnosis of CD to monitor the appropriateness of GFD and the patient’s nutritional status over time.

Published
2021

10. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome

Author

Duran, C., Ciucci, S., Palladini, A., Ijaz, U. Z., Zippo, A. G., Sterbini, F. P., Masucci, Luca, Cammarota, Giovanni, Ianiro, Gianluca, Spuul, P., Schroeder, M., Grill, S. W., Parsons, B. N., Pritchard, D. M., Posteraro, Brunella, Sanguinetti, Maurizio, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Cannistraci, C. V., Masucci L. (ORCID:0000-0002-8358-6726), Cammarota G. (ORCID:0000-0002-3626-6148), Ianiro G. (ORCID:0000-0002-8318-0515), Posteraro B. (ORCID:0000-0002-1663-7546), Sanguinetti M. (ORCID:0000-0002-9780-7059), Gasbarrini G., Gasbarrini A. (ORCID:0000-0002-7278-4823), Duran, C., Ciucci, S., Palladini, A., Ijaz, U. Z., Zippo, A. G., Sterbini, F. P., Masucci, Luca, Cammarota, Giovanni, Ianiro, Gianluca, Spuul, P., Schroeder, M., Grill, S. W., Parsons, B. N., Pritchard, D. M., Posteraro, Brunella, Sanguinetti, Maurizio, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Cannistraci, C. V., Masucci L. (ORCID:0000-0002-8358-6726), Cammarota G. (ORCID:0000-0002-3626-6148), Ianiro G. (ORCID:0000-0002-8318-0515), Posteraro B. (ORCID:0000-0002-1663-7546), Sanguinetti M. (ORCID:0000-0002-9780-7059), Gasbarrini G., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

The stomach is inhabited by diverse microbial communities, co-existing in a dynamic balance. Long-term use of drugs such as proton pump inhibitors (PPIs), or bacterial infection such as Helicobacter pylori, cause significant microbial alterations. Yet, studies revealing how the commensal bacteria re-organize, due to these perturbations of the gastric environment, are in early phase and rely principally on linear techniques for multivariate analysis. Here we disclose the importance of complementing linear dimensionality reduction techniques with nonlinear ones to unveil hidden patterns that remain unseen by linear embedding. Then, we prove the advantages to complete multivariate pattern analysis with differential network analysis, to reveal mechanisms of bacterial network re-organizations which emerge from perturbations induced by a medical treatment (PPIs) or an infectious state (H. pylori). Finally, we show how to build bacteria-metabolite multilayer networks that can deepen our understanding of the metabolite pathways significantly associated to the perturbed microbial communities.

Published
2021

17. Editorial - COVID-19 pandemic outbreak and the Latin rule of Bernard de Clairvaux. Have we forgotten the past?

Author

Franceschi, Francesco, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Franceschi F. (ORCID:0000-0001-6266-445X), Gasbarrini G., Gasbarrini A. (ORCID:0000-0002-7278-4823), Franceschi, Francesco, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Franceschi F. (ORCID:0000-0001-6266-445X), Gasbarrini G., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2020

18. Editorial - COVID-19 and the microbiota: New kids on the block

Author

Gasbarrini, Giovanni Battista, Dionisi, Tommaso, Franceschi, Francesco, Gasbarrini, Antonio, Gasbarrini G., Dionisi T., Franceschi F. (ORCID:0000-0001-6266-445X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Gasbarrini, Giovanni Battista, Dionisi, Tommaso, Franceschi, Francesco, Gasbarrini, Antonio, Gasbarrini G., Dionisi T., Franceschi F. (ORCID:0000-0001-6266-445X), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2020

34. Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions. (Liver Disease)

Author

Greco, A.V., Mingrone, G., Mari, A., Capristo, E., Manco, M., and Gasbarrini, G.

Subjects
Metabolic diseases -- Causes of -- Physiological aspects, Liver cirrhosis -- Physiological aspects, Health, Physiological aspects, Causes of
Abstract

Aims: Human liver cirrhosis is commonly associated with increased fasting and glucose induced insulin concentrations. However, whether the hyperinsulinoemia is a consequence of increased pancreatic insulin secretion, decreased hepatic insulin [...]

Published
2002

36. Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment

Author

Mikhailova, T. L., Sishkova, E., Poniewierka, E., Zhidkov, K. P., Bakulin, I. G., Kupcinskas, L., Lesniakowski, K., Grinevich, V. B., Malecka-Panas, E., Ardizzone, S., D’Arienzo, A., Valpiani, D., Koch, M., Denapiene, G., Vago, G., Fociani, P., Zerbi, P., Ceracchi, M., Camerini, R., and Gasbarrini, G.

Published
2011
Full Text
View/download PDF

42. Kinetics of dodecanedioic acid triglyceride in rats

Author

De Gaetano, A., Mingrone, G., Castagneto, M., Benedetti, G., Greco, A.V., and Gasbarrini, G.

Subjects
Rats -- Research, Triglycerides -- Research, Chemical reaction, Rate of -- Research, Biological sciences
Abstract

Research was conducted to examine the kinetics of a newly synthesized derivative of C-12, triglyceride of dodecanedioic acid (TGDA), in rats after a rapipd intravenous bolus injection. The measurement of TGDA and its hydrolysis products were calculated in plasma samples taken at different times via an improved high-performance liquid chromatographic technique. Results indicate that, in rats, C-12 administration achieves even higher rates of caloric delivery than glucose administration.

Published
1999

45. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference

Author

GASBARRINI, A., CORAZZA, G. R., GASBARRINI, G., MONTALTO, M., STEFANO, DI M., BASILISCO, G., PARODI, A., SATTA, P. U., VERNIA, P., ANANIA, C., ASTEGIANO, M., BARBARA, G., BENINI, L., BONAZZI, P., CAPURSO, G., CERTO, M., COLECCHIA, A., CUOCO, L., SARIO, DI A., FESTI, D., LAURITANO, C., MICELI, E., NARDONE, G., PERRI, F., PORTINCASA, P., RISICATO, R., SORGE, M., and TURSI, A.

Published
2009

48. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism: Multicentre prospective study by the ‘Nutritional Problems in Gastroenterology’ Section of the Italian Society of Gastroenterology (SIGE)

Author

Guglielmi, F.W., Panella, C., Buda, A., Budillon, G., Caregaro, L., Clerici, C., Conte, D., Federico, A., Gasbarrini, G., Guglielmi, A., Loguercio, C., Losco, A., Martines, D., Mazzuoli, S., Merli, M., Mingrone, G., Morelli, A., Nardone, G., Zoli, G., and Francavilla, A.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results